A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

• Status: Completed
• Trial end date: 2002-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to measure the safety and efficacy of three doses of varenicline for smoking cessation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• Subjects must have smoked on average of at least ten cigarettes per day during the past year

• Subjects must have no period of abstinence greater than three months in the past year

Exclusion Criteria:

• Subjects with any history of cardiovascular disease

• Myocardial infarction

• Significant arrhythmias

• Poorly controlled hypertension